[Shangrong Medical 2025 Semi-Annual Performance Forecast](index=1&type=section&id=Shenzhen%20Shangrong%20Medical%20Co.%2C%20Ltd.%202025%20Semi-Annual%20Performance%20Forecast) This report provides the preliminary performance forecast for Shenzhen Shangrong Medical Co., Ltd. for the first half of 2025, indicating a significant shift from profit to loss [Performance Forecast](index=1&type=section&id=I.%20Estimated%20Performance%20for%20the%20Current%20Period) The company anticipates a shift from profit to loss in the first half of 2025, with net profit attributable to shareholders projected to be a loss of 7.0 million to 9.5 million yuan, representing a significant year-over-year decline of 135.65% to 167.73% compared to the prior year's profit of 14.0266 million yuan, while net profit after deducting non-recurring gains and losses is expected to decline even more sharply by 518.36% to 713.25% 2025 Semi-Annual Performance Forecast | Item | Current Reporting Period (2025.01.01 - 2025.06.30) | Prior Year Period | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders of Listed Company** | Loss: 7.0 million — 9.5 million yuan | Profit: 14.0266 million yuan | | Year-over-Year Change | Decrease: 135.65% — 167.73% | - | | **Net Profit After Deducting Non-Recurring Gains and Losses** | Loss: 9.6594 million — 14.1594 million yuan | Profit: 2.3089 million yuan | | Year-over-Year Change | Decrease: 518.36% — 713.25% | - | | **Basic Earnings Per Share** | Loss: 0.006 — 0.011 yuan/share | Profit: 0.0166 yuan/share | [Communication with Accounting Firm](index=1&type=section&id=II.%20Communication%20with%20Accounting%20Firm) The company explicitly states that the financial data in this performance forecast has not been pre-audited by a certified public accountant, and its accuracy is subject to uncertainty - The financial data related to this performance forecast has not been pre-audited by a certified public accountant[4](index=4&type=chunk) [Explanation of Performance Changes](index=1&type=section&id=III.%20Explanation%20of%20Performance%20Changes) The company attributes the shift from profit to loss primarily to three negative factors: a significant decline in core medical professional engineering revenue, a simultaneous decrease in both volume and price for export medical consumables, and a sharp reduction in non-operating income such as government subsidies - The primary reasons for the company's loss include[5](index=5&type=chunk) - Medical professional engineering revenue: Revenue completed and recognized in the current reporting period decreased by **72%** compared to the prior year period[5](index=5&type=chunk) - Export business: Sales volume and profit margins of medical consumable products further declined[5](index=5&type=chunk) - Non-operating income: Income from government subsidies and write-offs of receivables decreased by approximately **90%** compared to the prior year period[5](index=5&type=chunk) [Other Relevant Information](index=1&type=section&id=IV.%20Other%20Relevant%20Information) The company emphasizes that this performance forecast is a preliminary estimate by the finance department, with final accurate financial data to be disclosed in the official "2025 Semi-Annual Report," and advises investors to be aware of investment risks and rely on information published by the company in designated media - This performance forecast is a preliminary estimate by the company's finance department and has not been audited by an auditing firm[6](index=6&type=chunk) - The company reminds investors to rely on information published in designated media such as "China Securities Journal," "Securities Times," and Juchao Information Network, and to be aware of investment risks[7](index=7&type=chunk)

Core Viewpoint - Shenzhen Shangrong Medical Co., Ltd. announced a cash dividend distribution plan for the fiscal year 2024, with a total cash dividend of 6,755,714.22 yuan (including tax), distributing 0.08 yuan per 10 shares to shareholders [1][2][3]. Summary by Sections Dividend Distribution Plan - The company will distribute a cash dividend of 0.08 yuan per 10 shares, based on a total share count of 844,464,278 shares after excluding 1,030,300 shares held in the repurchase account [1][2][3]. - The total cash dividend amount is expected to be 6,755,714.22 yuan (including tax) [1][2]. Share Count and Adjustments - The total share count remains unchanged post-distribution, but the cash dividend per share will decrease due to the exclusion of repurchased shares [2][3]. - The calculation for the ex-dividend price will be based on the total share count, including repurchased shares, resulting in an adjusted price of approximately 0.079902 yuan per share [2][3][6]. Key Dates - The record date for the dividend distribution is set for July 17, 2025, and the ex-dividend date is July 18, 2025 [3][4]. Dividend Recipients - The dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shenzhen Branch, as of the record date [4][5]. Payment Method - Cash dividends will be directly credited to shareholders' accounts through their custodial securities companies or other custodial institutions [6].

证券代码：002551 证券简称：尚荣医疗 公告编号：2025-036 深圳市尚荣医疗股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、根据《上市公司股份回购规则》、《深圳证券交易所上市公司自律监管 指引第9号——回购股份》等相关规定，上市公司回购专用账户中的股份不享有 利润分配等权利。深圳市尚荣医疗股份有限公司（以下简称"公司"或"本公司"） 通过回购专用证券账户持有的本公司股份1,030,300 股，不参与本次权益分派。 因此，本次权益分派以公司现有总股本845,494,578股剔除回购专用证券账户持有 的1,030,300股后共计844,464,278股为基数，向全体股东每10股派发现金红利0.08 元（含税），预计派发现金股利6,755,714.22元(含税)。本年度不送红股，不以 资本公积转增股本。 2、鉴于公司回购股份不享有利润分配的权利，根据股票市值不变原则，实 施权益分派前后公司总股本保持不变，现金分红总额分摊到每一股的比例将减小。 本次权益分派实施后计算除权除息价格时，按公司总股本（ ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Shangrong Medical, which has a current PE ratio of 150.86, significantly higher than the industry average of 51.42 [1][2] - As of July 7, Shangrong Medical's stock closed at 3.99 yuan, marking a 2.57% increase, with a total market capitalization of 3.374 billion yuan [1] - The company has seen a net inflow of 10.55 million yuan in principal funds on July 7, with a total inflow of 9.69 million yuan over the past five days [1] Group 2 - Shangrong Medical reported a revenue of 280 million yuan for Q1 2025, reflecting a year-on-year increase of 30% [2] - The net profit for the same period was 13.96 million yuan, showing a year-on-year growth of 0.58%, with a sales gross margin of 15.27% [2] - The company is recognized as a national high-tech enterprise and has accumulated over 180 patents, which contribute to its ongoing development [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Shangrong Medical, indicating a significant increase in stock price and a high PE ratio compared to industry averages [1][2] - As of June 23, Shangrong Medical's stock closed at 3.67 yuan, up 3.67%, with a rolling PE ratio of 138.76 times and a total market value of 3.103 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 48.89 times and a median of 35.79 times, placing Shangrong Medical at the 111th position in the industry ranking [1][2] Group 2 - For the first quarter of 2025, Shangrong Medical reported an operating income of 280 million yuan, a year-on-year increase of 30%, and a net profit of 13.9642 million yuan, reflecting a year-on-year growth of 0.58% [2] - The company's sales gross margin stands at 15.27% [2] - Shangrong Medical is recognized as a national high-tech enterprise and has received numerous awards and honors, including over 180 patents, which contribute to its ongoing development [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Shangrong Medical, indicating a high PE ratio compared to industry averages [1][2] - As of June 16, the closing price of Shangrong Medical was 3.75 yuan, with a PE ratio of 141.78 and a total market capitalization of 3.171 billion yuan [1] - The average PE ratio for the medical device industry is 49.56, with a median of 36.18, positioning Shangrong Medical at the 111th rank within the industry [1][2] Group 2 - For Q1 2025, Shangrong Medical reported an operating income of 280 million yuan, a year-on-year increase of 30%, and a net profit of 13.9642 million yuan, reflecting a year-on-year growth of 0.58% [2] - The company's gross profit margin stands at 15.27% [2] - The company has a total of 58,323 shareholders, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] Group 3 - Shangrong Medical specializes in the production and sales of medical products, medical services, and health industry operations [1] - The company is recognized as one of the earliest to introduce clean technology into hospital operating rooms and has received multiple national honors for its innovative products [1] - Shangrong Medical holds over 180 patents, contributing to its ongoing development and innovation [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Shangrong Medical, indicating a significant disparity between its price-to-earnings (PE) ratio and the industry average [1][2] - As of May 26, the closing price of Shangrong Medical was 3.62 yuan, with a PE ratio of 136.87, significantly higher than the industry average of 48.92 [1][2] - The company's total market capitalization is reported at 30.61 billion yuan, ranking it 111th in the medical device industry [1][2] Group 2 - For Q1 2025, Shangrong Medical reported an operating income of 280 million yuan, reflecting a year-on-year increase of 1.30%, and a net profit of 13.96 million yuan, with a slight increase of 0.58% [2] - The sales gross margin for the company stands at 15.27% [2] - The company has a total of 58,323 shareholders, with an average holding value of 352,800 yuan and an average shareholding quantity of 27,600 shares [1]

Summary of Key Points Core Viewpoint - On May 23, 2025, Shangrong Medical (002551) reported a closing price of 3.71 yuan, reflecting a 1.37% increase, with a turnover rate of 11.9% and a trading volume of 727,200 shares, amounting to a transaction value of 270 million yuan [1]. Trading Information - On the same day, the fund flow for Shangrong Medical indicated a net inflow of 17.2367 million yuan from institutional investors, while retail investors experienced a net outflow of 9.9439 million yuan and speculative funds saw a net outflow of 7.2928 million yuan [2][3]. Company Announcements - The eighth temporary meeting of the eighth board of directors of Shenzhen Shangrong Medical Co., Ltd. was held on May 23, 2025, where it was approved to apply for a loan credit limit from Huishang Bank for its subsidiary Hefei Purde Medical Supplies Co., Ltd. The loan amount will not exceed 13 million yuan (or equivalent foreign currency) with a term of 12 months, intended for working capital loans, export accounts receivable pool financing, bank acceptance bill exposure, and letter of credit exposure [2][3]. - The loan will be secured by the subsidiary's own land and property, and the approval was within the board's authority, requiring no shareholder meeting for further approval, with a voting result of 9 in favor, 0 against, and 0 abstentions [2].

Core Viewpoint - The company has shown significant growth in revenue and profit, with a focus on expanding its overseas market presence, particularly in Europe and Southeast Asia, which is expected to contribute to stable and gradual recovery in earnings [1][2]. Group 1: Performance Disclosure Highlights - For the reporting period, the company achieved total operating revenue of 1,448.21 million yuan, representing a year-on-year increase of 21.40% [1][4]. - Operating profit reached 33.54 million yuan, up 127.67% year-on-year [1][4]. - Net profit attributable to shareholders was 22.28 million yuan, reflecting a year-on-year growth of 114.97% [1][4]. - Total assets amounted to 3,877.89 million yuan, with total liabilities of 1,102.05 million yuan, resulting in a debt-to-asset ratio of 28.42% [1]. Group 2: Institutional Research Highlights - The significant revenue growth in Q4 2024 is primarily attributed to the completion of hospital engineering projects and revenue recognition [1][4]. - The company’s disposable medical consumables business is expected to peak in Q4, contributing to substantial revenue increases [1]. Group 3: Company Announcements Summary - The company’s subsidiary, Hefei Purde Medical Supplies Co., Ltd., has applied for a loan credit limit of up to 13 million yuan from Huishang Bank, with a loan term of 12 months [3][4]. - The loan will be secured by the subsidiary's own land and property, and the board has authorized the management to handle all loan matters within the approved credit limit [3].

Group 1 - The company held its eighth temporary board meeting on May 23, 2025, with all nine directors present, complying with relevant laws and regulations [1][2] - The board approved a resolution for the company's subsidiary, Hefei Puder Medical Supplies Co., Ltd., to apply for a loan credit limit of up to RMB 13 million from Huishang Bank, with a loan term of 12 months [1][2] - The loan will be secured by the subsidiary's own land and property, and the specific terms will be defined in the business contract [1][2] Group 2 - The application for the loan credit limit is to continue the existing credit limit and does not involve any new credit [2] - The board authorized the management of Puder Medical to handle all loan matters within the approved credit limit [2] - The approval of the loan credit limit does not require submission to the shareholders' meeting as it falls within the board's authority [2]